Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

Executive Summary

Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in Phase III for ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling without pivotal data in this population.

Advertisement

Related Content

AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer
US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval
Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Clovis Transitions To Commercial Stage On Rubraca Approval
Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Lynparza Approval Shows Benefit/Risk Contrast In Maintenance, Relapse Settings
AstraZeneca’s Olaparib Clears FDA For Later Therapy Line In Ovarian Cancer
AstraZeneca Back In The PARP Mix With Olaparib In Ovarian Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel